Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:58 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 156 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Medication safety review Clear all

Conditions: Obesity, Weight Gain, Disordered Eating, Eating Disorder
Interventions: Interpersonal Psychotherapy-Weight Gain, Health Education; Behavioral · Other
Lead sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine; Other
Eligibility: 12 Years to 17 Years · Female only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Fort Belvoir, Virginia

Conditions: Cachexia
Interventions: GSK2881078, Placebo, Itraconazole; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 108 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Bronchopulmonary Dysplasia
Interventions: Furosemide Cohort 1, Furosemide Cohort 2, Furosemide Cohort 3, Placebo; Drug · Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 7 Days to 28 Days
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 21
States / cities: Little Rock, Arkansas • Loma Linda, California • Jacksonville, Florida + 17 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: VTx-002, Preventative (Prophylactic) Medication - Corticosteroids: Methylprednisolone; Genetic · Drug
Lead sponsor: Vector Y Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 6
States / cities: Phoenix, Arizona • San Diego, California • Jacksonville, Florida + 3 more

Conditions: Head and Neck Cancer (H&N), Oral Mucositis (Ulcerative) Due to Radiation, Stomatitis (Oral Mucositis), Xerostomia Due to Radiotherapy, Radiation Toxicity
Interventions: ORAL CARE PRODUCT KIT; Other
Lead sponsor: UNCANCER LLC; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Clearwater, Florida

Conditions: Cerebral Edema, Brain Metastases
Interventions: Glyburide, Placebo; Drug · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Prostate Cancer Metastatic
Interventions: ARV-766, Abiraterone, Corticosteroid (e.g., prednisone/prednisolone), Androgen Deprivation Therapy (ADT); Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 17
States / cities: Duarte, California • La Jolla, California • Santa Monica, California + 14 more

Conditions: Fall
Interventions: Fall Prevention; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 65 Years and older
Enrollment: 197 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 3
States / cities: Aurora, Colorado • Providence, Rhode Island

Conditions: Treatment-resistant Depression
Interventions: Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 10
States / cities: Birmingham, Alabama • Orange, California • San Rafael, California + 7 more

Conditions: Breast Cancer, Head and Neck Squamous Cell Carcinoma, Non Small Cell Lung Cancer, Hepatocellular Cancer, Colorectal Cancer, Gastric Adenocarcinoma, Melanoma, Advanced Cancer
Interventions: TTI-101; Drug
Lead sponsor: Tvardi Therapeutics, Incorporated; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 2
States / cities: Houston, Texas • San Antonio, Texas

Conditions: HIV-1-infection
Interventions: ISL/LEN, B/F/TAF, PTM B/F/TAF, PTM ISL/LEN; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 609 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 60
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 50 more

Conditions: Human Immunodeficiency Virus
Interventions: Baricitinib 2 MG Oral Tablet, Placebo; Drug
Lead sponsor: William Tyor; Other
Eligibility: 18 Years to 65 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Mitral Regurgitation, Valvular Heart Disease, Heart Failure
Interventions: MitraClip, Moderate MR; Device · Other
Lead sponsor: Inova Health Care Services; Other
Eligibility: 18 Years to 99 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Falls Church, Virginia

Conditions: Suicide, Attempted, Drug Use, Alcohol; Use, Problem
Interventions: Brief intervention to prevent suicide attempt, Enhanced treatment as usual; Behavioral
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Lysosomal Diseases, Gangliosidosis, GM1
Interventions: AAV9-GLB1, Abdominal ultrasound, Rituximab, Sirolimus, Methylprednisolone, Prednisone, Audiology assessment with ABR, Bone density scan (DEXA), Electrocardiogram (EKG), Echocardiogram, Electroencephalogram (EEG) awake and extended overnight, Laboratory tests, Lumbar puncture, Brain MRI/MRS/fMRI, Neurocognitive testing, Neurology exam, PICC or other Central line placement, Skeletal survey, Skin biopsy, Speech and modified barium swallow study, Ophthalmology exam; Biological · Procedure · Drug + 3 more
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 6 Months to 12 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Major Depressive Disorder
Interventions: Vilazodone; Viibryd, Paroxetine; Paxil; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 60 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Frail Elderly Syndrome
Interventions: Frailty Prevention Program; Behavioral
Lead sponsor: Wayne State University; Other
Eligibility: 55 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Ebola Virus Disease, Marburg Virus Disease
Interventions: cAd3-Marburg, cAd3-EBO-S; Biological
Lead sponsor: Albert B. Sabin Vaccine Institute; Other
Eligibility: 18 Years to 50 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Major Depressive Disorder
Interventions: CYB003, Psychotherapy, Placebo, Psychological Support; Drug · Behavioral
Lead sponsor: Cybin IRL Limited; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 3
States / cities: Atlanta, Georgia • Decatur, Georgia • Eatontown, New Jersey

Conditions: Obesity, Morbid, Obesity, Decision Aids, Bariatric Surgery
Interventions: Video Decision Aid, Booklet Decision Aid; Other
Lead sponsor: Kaiser Permanente; Other
Eligibility: 20 Years to 65 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Chronic Hepatitis C
Interventions: BMS-650032, BMS-790052, BMS-791325, Ribavirin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 26
States / cities: Birmingham, Alabama • Coronado, California • Los Angeles, California + 19 more

Conditions: Obsessive Compulsive Disorder (OCD), Anxiety Disorder of Childhood or Adolescence, Social Anxiety Disorder of Childhood, Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder, Panic Disorder, Panic Attacks, Panic Disorder (With or Without Agoraphobia), Phobia, Specific
Interventions: Parent Coached Exposure Therapy, Family Based, Internet-Based Cognitive Behavioral Therapy; Behavioral
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 7 Years to 17 Years
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Locally Advanced Solid Tumor
Interventions: AN2025, AN0025, Atezolizumab 1200 mg in 20 ML Injection; Drug
Lead sponsor: Adlai Nortye Biopharma Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 5
States / cities: Aurora, Colorado • Lake Mary, Florida • New Brunswick, New Jersey + 2 more

Conditions: Respiratory Disease, Cardiovascular Diseases, Neurologic Disorder, Dementia, Cancer
Interventions: Medication safety review; Other
Lead sponsor: Tabula Rasa HealthCare; Industry
Eligibility: 18 Years to 88 Years
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Tucson, Arizona

Search by objective public record fields.

Preventing Obesity in Military Communities, Adolescents

Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic Study of GSK2881078 and Study to Evaluate the Effect of CYP3A4 Inhibition on PK of GSK2881078

Safety of Furosemide in Premature Infants at Risk of Bronchopulmonary Dysplasia (BPD)

Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS

Oral Care Program for Mouth Side Effects During Head and Neck Radiation Therapy

Glyburide vs Placebo as Prophylaxis Against Cerebral Edema in Patients Receiving Radiosurgery for Brain Metastases (RAD 1502/UAB 1593)

A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer

The Geriatric Acute & Post-acute Care Coordination Program for Fall Prevention in the Emergency Department II

A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1

Baricitinib for Reduction of HIV - CNS

In Search of Best Practices for Patients With Heart Failure and Secondary Mitral Regurgitation: An Evaluation of the Inova Heart Failure Treatment Algorithm

Brief New Treatment for Suicide Attempts

A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis

Vilazodone for Treatment of Geriatric Depression

Frailty Prevention Program to Prevent Frailty Among Older African Americans

Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults

A Study of a Psilocybin Analog (CYB003) in Healthy Participants With and Without Major Depressive Disorder

Study Testing Patient Decision Tools Related to the Risks and Benefits of Weight Loss Surgery

Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications

Comparative Effectiveness of Internet-based Versus Parent-Coached Cognitive-Behavioral Therapy For Children and Adolescents With Anxiety and OCD

Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors

Hospice Quality Score Assessment Post Pharmacist Intervention